Peer Review History
| Original SubmissionMarch 29, 2020 |
|---|
|
PONE-D-20-08967 Chronic Diseases impacting the income and expenditure of chronically-ill people in Sri Lanka PLOS ONE Dear Dr. Jayathilaka, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 20 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Khurshid Alam, Ph. D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please ensure that you include a title page within your main document. We do appreciate that you have a title page document uploaded as a separate file, however, as per our author guidelines (http://journals.plos.org/plosone/s/submission-guidelines#loc-title-page) we do require this to be part of the manuscript file itself and not uploaded separately. Could you therefore please include the title page into the beginning of your manuscript file itself, listing all authors and affiliations. 3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide. 4. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4, 5, 6, & 7 in your text; if accepted, production will need this reference to link the reader to the Table. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This paper, using ANOVA technique analyses the household income and expenditure (total and per-capita) across a number of chronic disease types. The data used for the analysis is suitable for such analysis and techniques used are reasonable. This paper analyses a unique topic with respect to Sri Lanka, and hence this research makes a significant contribution to the literature. However, I would like to raise the following concerns that authors need to address. Introduction and objectives The problem statement and objective sections have significant repetitions. Unless it is a requirement of the journal, the paper will read better if the authors combine these two sections with the introduction section and remove repetitive sentences. I have some concerns about the objective of the study. While in few places, authors claim that they investigate the “differences in the level of income and expenditure of people diagnosed with chronic illnesses”, in the hypothesis they are testing, they note that the hypothesis is that “There is an impact of differences in the level of income and expenditure among chronically-ill people in Sri Lanka”. In my view, authors are not investigating the impact of chronic diseases on income and expenditure levels. The paper analyses the differences in income and expenditure across different types of chronic illnesses. This point needs to be clarified and expressed clearly. In another place, they note that “this research will be carried out by examining the growing toll of chronic diseases and its relevance to poverty”. However, authors neither present any estimated results anywhere how their findings are related to poverty nor how they define poor/non-poor. One way to look into this can be whether the per-capita income/per-capita expenditure in households that have chronically ill people is less than the official poverty line? Authors present a number of arguments without any references, for example, “According to several investigations conducted, it was revealed that the availability of essential laboratory facilities and drugs for various chronic diseases is limited to a high extent.” Literature review While this specific research topic may have not been investigated in Sri Lanka, some literature even remotely related to the context of Sri Lanka, South Asia, etc could be discussed and compared and contrasted with the findings of this paper. Data The discussion of the summary statistics is more appropriate to be included in the Data section rather than in the results and discussion section. Results and discussion In the results and discussion section, authors note that “Thus, this study reveals that even though most of the chronic patients were found to be non-poor, the chronic condition and its consequences have significantly affected their level of income. Further, it has proved the fact that chronic diseases have an impact towards the income of victims despite the fact of being poor [6]”. Firstly, these two sentences are contradictory. Secondly, I am not sure how the authors relate their findings to poor and non-poor as this paper doesn’t analyse the differences between poor and non-poor. The authors discuss how chronic diseases may have implications for food and non-food expenditures. For example, they note that "This has caused to have a significant impact of chronic illnesses towards food expenditure." However, they neither provide references for these claims nor provide estimated results in the current study. It would be interesting to know whether there are any such differences in the context of Sri Lanka. Conclusion In the introduction, authors note that “this study aims to contribute its findings to policymakers and responsible authorities to devise feasible policies and initiatives.” However, they do not discuss the policy implications of their findings explicitly following the results and discussion section. Minor comments Automatic links to some tables are broken. One-way ANOVA tests were conducted to further clarify the significance towards the sources of income; employment income, agricultural income, non-agricultural income, other income, ad hoc income and non-monetary income from food and non-food expenditure, . …four out of five chronic disease deaths that occur in the world today spur from low and middle income countries like ours.? Sri Lanka? Reviewer #2: This manuscript addresses an important topic “Chronic Diseases impacting the income and expenditure of chronically-ill people in Sri Lanka” using Sri Lankan household data. It is useful for understanding of impacts of chronic diseases on household income and expenses among Sri Lankan households. It is of value because Sri Lanka government try to improve health sector in general and introduce several recent health policies such as lowering prices of medicine and restriction of charges by the private hospitals. It is well written, and well structured. However, I would recommend the authors to consider a number of major revisions for further polishing before publishing in PlosOne. 1. Authors have included several literature related to economic impacts of chronic diseases but several recent papers on Sri Lankan context are missing. For example, Kumara and Samaratunge (2016), Kumara and Samaratunge (2017), Pallegedara and Grimm (2018), Pallegedara (2018) also examined the out-of-pocket health care expenses and welfare impacts due to chronic health diseases in Sri Lanka context. Thus, authors need to add these papers when discussing the related Sri Lankan literature. 1. Kumara, A. S., & Samaratunge, R. (2016). Patterns and determinates of out-of-pocket health care expenditure in Sri Lanka: Evidence from household surveys. Health Policy and Planning, 31(8), 970-983. 2. Kumara, A. S., & Samaratunge, R. (2017). Impact of ill-health on household consumption in Sri Lanka: Evidence from household survey data. Social science & medicine (1982), 195, 68. 3. Pallegedara, A., & Grimm, M. (2018). Have out‐of‐pocket health care payments risen under free health care policy? The case of Sri Lanka. The International journal of health planning and management, 33(3), e781-e797. 4. Pallegedara, A. (2018). Impacts of chronic non-communicable diseases on households’ out-of-pocket healthcare expenditures in Sri Lanka. International Journal of Health Economics and Management. Vol. 18, No. 3. pp. 301-319. DOI: https://doi.org/10.1007/s10754-018-9235-2 2. In this study, authors only describe analytical tools they used. However, they should add a conceptual/analytical framework to explain the choice of variables both independent and dependent variables they used in empirical analysis. Authors can link previous literature regarding the variable selection and should provide more justification for the choice of variables based on the conceptual framework. 3. Authors only used ANOVA method to analyze the data. ANOVA is mainly descriptive tool to explore data. Thus, they need to justify why they used ANOVA over other statistical methods such as regression analysis. 4. Authors did not explain policy implications of their results. Thus, they need to add policy implications and/or recommendations based on the results they found. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 1 |
|
Chronic Diseases: An Added Burden to Income and Expenses of Chronically-ill People in Sri Lanka PONE-D-20-08967R1 Dear Dr. Jayathilaka, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Khurshid Alam, Ph. D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: No comments. Authors have addressed all my comments and I am satisfied with the revised version. All the best! Reviewer #2: Authors have sufficiently revised the manuscript according to previous review. Therefore, I would like to accept the revised manuscript. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No |
| Formally Accepted |
|
PONE-D-20-08967R1 Chronic Diseases: An Added Burden to Income and Expenses of Chronically-ill People in Sri Lanka Dear Dr. Jayathilaka: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Khurshid Alam Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .